Eli Lilly’s LLY0.57%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

This is an opinion column. It’s a juicy Tuesday in April when a reader thinks I might have a legal case against the University of Alabama. Were reporters held against their will at A-Day? Yes. Does ...

Eli Lilly’s LLY0.66%increase; green up pointing triangle Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company ...

Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city. Indianapolis-based Lilly will celebrate 150 ...

Al Benninger served as University of Louisville basketball's chief statistician for five decades, setting the standard for stats crews delivering objective measures to coaches and broadcasters.

The Indiana-based pharma giant’s 150 Years of Everything Else campaign will be heavily featured during the NCAA men’s and women’s Final Four basketball games this weekend. The spot was produced by ...

Eli Lilly opposes the White House's push to codify 'most favored nation' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...

Eli Lilly said on Tuesday it would buy Centessa ⁠Pharmaceuticals ‌in ⁠a deal valued at up to $7.8 billion as the U.S. drugmaker looks to diversify beyond its metabolic portfolio and expand into ...

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...

This is an opinion column. Michigan is in the Final Four with a star transfer from UAB. I’m happy for Yaxel Lendeborg, who developed his game in Birmingham, but part of me is a little jealous that the ...

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech ...